Skip to main content

Advertisement

SpringerLink
Log in

Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?

  • Brief Report
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

We each have nephrotic patients who become steroid dependent and in whom multiple immunosuppressive agents are employed. There is a need to balance possible therapeutic benefits with drug toxicity. This case report describes such a patient, who has suffered from nephrotic syndrome for over 11 years and had become resistant to the usual therapies. He was therefore given a single dose of the anti-CD20 drug rituximab, to which he showed a prompt response, leaving him free of proteinuria for the past 10 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Sharma M, Sharma R, McCarthy ET, Savin VJ (1999) ‘The FSGS factor’: enrichment and in vivo effect of activity from focal segmental glomerulosclerosis factor. J Am Soc Nephrol 10:552–561

    CAS  PubMed  Google Scholar 

  2. Artero ML, Sharma R, Savin VJ, Vincenti F (1994) Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 23:574–581

    CAS  PubMed  Google Scholar 

  3. Tanaka R, Yoshikawa N, Nakamura H, Ito H (1992) Infusion of peripheral blood mononuclear cell products from nephrotic children increases albuminuria in rats. Nephron 60:35–41

    CAS  Google Scholar 

  4. Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M (1991) A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 40:453–460

    CAS  PubMed  Google Scholar 

  5. Couser W, Badger A, Cooperband S, Stilmand M, Jermanovich N, Aurora S, Doner D, Schmitt G (1977) Hodgkin’s disease and lipoid nephrosis. Lancet i:912–913

    Google Scholar 

  6. Belghiti D, Vernant JP, Hirbec G, Gubler MC, Andre C, Sobel A (1981) Nephrotic syndrome associated with T-cell lymphoma. Cancer 47:1878–1882

    CAS  PubMed  Google Scholar 

  7. McDonald P, Kalra PA, Coward RA (1992) Thymoma and minimal-change glomerulonephritis. Nephrol Dial Transplant 7:357–359

    CAS  PubMed  Google Scholar 

  8. Hardwicke J, Soothill J, Squire J, Holti G (1959) Nephrotic syndrome associated with pollen hypersensitivity. Lancet i:450

    Google Scholar 

  9. Dantal J, Bigot E, Bogers W, Testa A, Kriaa F, Jacques Y, Hurault de Ligny B, Niaudet P, Charpentier B, Soulillou JP (1994) Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 330:7–14

    CAS  PubMed  Google Scholar 

  10. Dantal J, Godfrin Y, Koll R, Perretto S, Naulet J, Bouhours JF, Soulillou JP (1998) Antihuman immunoglobulin affinity immunoabsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J Am Soc Nephrol 9:1709–1715

    CAS  PubMed  Google Scholar 

  11. Szeto C, Gillespie KM, Mathieson PW (2000) Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance. Immunology 100:217–224

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Kimata H, Fujimoto M, Furusho K (1995) Involvement of interleukin (IL)-13, but not IL-4, in spontaneous IgE and IgG4 production in nephrotic syndrome. Eur J Immunol 25:1497–1501

    CAS  PubMed  Google Scholar 

  13. Yap HK, Cheung W, Murugasu B, Sim SK, Seah CC, Jordan SC (1999) Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 10:529–537

    CAS  PubMed  Google Scholar 

  14. Kemper MJ, Meyer-Jark T, Lilova M, Muller-Wiefel DE (2003) Combined B- and T-cell activation in childhood steroid-sensitive nephrotic syndrome. Clin Nephrol 60:242–247

    CAS  PubMed  Google Scholar 

  15. Benz K, Dötsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after Rituximab therapy. Pediatr Nephrol 19:794–797

    PubMed  Google Scholar 

  16. Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M (2005) Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 20:1660–1663

    Google Scholar 

  17. Pescovitz MD, Book BK, Sidner RA (2006) Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 354:1961–1963

    CAS  PubMed  Google Scholar 

  18. Gilbert RD, Rigden SPA (2006) Rituximab therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol 21:1698–1700

    PubMed  Google Scholar 

  19. Westphal S, Hansson S, Mjörnstedt L, Mölne J, Swerkersson S, Friman S (2006) Early recurrence nephrotic syndrome (immunoglobulin M nephropathy) after renal transplantation successfully treated with combinations of plasma exchange, immunoglobulin, and rituximab. Transplant Proc 38:2659–2660

    CAS  PubMed  Google Scholar 

  20. Kemper MJ, Möller K, Ludwig K, Rink N, Müller-Wiefel (2006) Rituximab (RTX) in the treatment of refractory steroid sensitive nephrotic syndrome (abstract). Pediatr Nephrol 21:1528

    Google Scholar 

  21. Dallochio IA, Trimoreau F, Feuillard J, Guigonis V (2006) A case of steroid-dependent nephrotic syndrome treated with rituximab (abstract). Pediatr Nephrol 21:1615

    Google Scholar 

  22. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Newman RA, Hanna N, Anderson DR (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445

    CAS  PubMed  Google Scholar 

  23. Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC, Plumas J (2003) In vitro mechanisms of action of Rituximab on primary non-Hodgkins lymphomas. Blood 101:949–954

    CAS  PubMed  Google Scholar 

  24. Maloney DG, Smith B, Rose A (2002) Rituximab: mechanism of action and resistance. Semin Oncol 29 [Suppl 2]:2–9

    CAS  PubMed  Google Scholar 

  25. Robak T (2004) Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 72:79–88

    CAS  PubMed  Google Scholar 

  26. Raj A, Bertolone S, Cheerva A (2004) Successful treatment of refractory autoimmune hemolytic anemia with monthly Rituximab following nonmyeloablative stem cell transplantation for sickle cell disease. J Pediatr Hematol Oncol 26:312–314

    PubMed  Google Scholar 

  27. Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, Jankovic M, Pierani P, De Stefano P, Bonora MR, Locatelli F (2003) Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 101:3857–3861

    CAS  PubMed  Google Scholar 

  28. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A (2001) Treatment of childhood autoimmune haemolytic anaemia with Rituximab. Lancet 358:1511–1513

    CAS  PubMed  Google Scholar 

  29. Saleh MN, Gutheil J, Moore M, Bunch PW, Butler J, Kunkel L, Grillo-Lopez AJ, LoBuglio AF (2000) A pilot study of the anti-CD20 monoclonal antibody Rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 27:99–103

    CAS  PubMed  Google Scholar 

  30. Stasi R, Pagano A, Stipa E, Amadori S (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98:952–957

    CAS  PubMed  Google Scholar 

  31. Zaja F, Vianelli N, Sperotto A, De Vita S, Iacona I, Zaccaria A, Masolini P, Tomadini V, Tani M, Molinari AL, Baccarani M, Fanin R (2003) B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica 88:538–546

    PubMed  Google Scholar 

  32. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, Bussel JB (2004) The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 125:232–239

    CAS  PubMed  Google Scholar 

  33. Levine TD, Pestronk A (1999) IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 52:1701–1704

    CAS  PubMed  Google Scholar 

  34. Pestronk A, Florence J, Miller T, Choksi R, Al Lozi MT, Levine TD (2003) Treatment of IgM antibody associated polyneuropathies using Rituximab. J Neurol Neurosurg Psychiatry 74:485–489

    CAS  PubMed  PubMed Central  Google Scholar 

  35. Rojas-Garcia R, Gallardo E, de Andres I, de Luna N, Juarez C, Sanchez P, Illa I (2003) Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to Rituximab. Neurology 61:1814–1816

    CAS  PubMed  Google Scholar 

  36. Renaud S, Gregor M, Fuhr P, Lorenz D, Deuschl G, Gratwohl A, Steck AJ (2003) Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 27:611–615

    CAS  PubMed  Google Scholar 

  37. Nobile-Orazio E (2004) IgM paraproteinaemic neuropathies. Curr Opin Neurol 17:599–605

    CAS  PubMed  Google Scholar 

  38. Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI, Weksler BB, Schechter GP (2002) Rituximab in the treatment of acquired factor VIII inhibitors. Blood 100:3426–3428

    CAS  PubMed  Google Scholar 

  39. Keogh KA, Wylam ME, Stone JH, Specks U (2005) Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody associated vasculitis. Arthritis Rheum 52:262–268

    PubMed  Google Scholar 

  40. Eriksson P (2005) Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with Rituximab. J Intern Med 257:540–548

    CAS  PubMed  Google Scholar 

  41. Stahl HD, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Edwards JCW, Clase DR, Stevens RM, Shaw TM (2003) Rituximab in rheumatoid arthritis: efficacy and safety from a randomized controlled trial. Ann Rheum Dis 62 [Suppl]:0P004

    Google Scholar 

  42. Shaw T, Quan J, Totoritis MC (2003) B cell therapy for rheumatoid arthritis: the Rituximab (anti-CD20) experience. Ann Rheum Dis 62 [Suppl 2]:ii55–ii59

    CAS  PubMed  PubMed Central  Google Scholar 

  43. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581

    CAS  PubMed  Google Scholar 

  44. DeVita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G (2002) Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 46:2029–2033

    CAS  Google Scholar 

  45. Tuscano JM (2002) Successful treatment of infliximab-refractory rheumatoid arthritis with Rituximab. Arthritis Rheum 46:3420

    Google Scholar 

  46. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA (2002) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46:2673–2677

    PubMed  Google Scholar 

  47. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, Looney RJ (2003) The relationship of FcγRIIIa genotype to degree of B cell depletion by Rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 48:455–459

    CAS  PubMed  Google Scholar 

  48. Eisenberg R (2003) Mechanisms of autoimmunity. Immunol Res 27:203–218

    CAS  PubMed  Google Scholar 

  49. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of Rituximab. Arthritis Rheum 50:2580–2589

    CAS  PubMed  Google Scholar 

  50. Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, Tullus K (2005) B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 52:3168–3174

    CAS  PubMed  Google Scholar 

  51. Johnson PWM, Glennie MJ (2001) Rituximab; mechanisms and applications. Br J Cancer 85:1619–1623

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Martin F, Chan AC (2004) Pathogenic roles of B cells in human autoimmunity; insights from the clinic. Immunity 20:517–527

    CAS  PubMed  Google Scholar 

  53. Silverman GJ, Carson DA (2003) Roles of B cells in rheumatoid arthritis. Arthritis Res Ther 5 [Suppl 4]:S1–S6

    PubMed  PubMed Central  Google Scholar 

  54. Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G, Isenberg DA (2004) B lymphocyte depletion in the treatment of systemic lupus erythematosus. Arthritis Rheum 50:S447

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Children’s Kidney Centre, University Hospital of Wales, Heath Park, Cardiff, CF14 4XW, UK

    Graham C. Smith

Authors
  1. Graham C. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Graham C. Smith.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smith, G.C. Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?. Pediatr Nephrol 22, 893–898 (2007). https://doi.org/10.1007/s00467-006-0427-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-006-0427-5

Keywords

Search

Navigation